ClinicalTrials.gg

Dyspepsia clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 372 studies for Dyspepsia across more than 10 countries. 66 are recruiting or about to start. 272 of them are mainly about Dyspepsia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13.

Status

Completed
211
Status unknown
58
Recruiting
46
Terminated
19
Not yet recruiting
16
Withdrawn
9

Phase

Phase 4
64
Phase 3
55
Phase 2
42
Phase 1
20
Early Phase 1
2

Where

United States
76
China
58
Korea, Republic of
28
Belgium
21
Spain
13
Netherlands
10

Who develops what

Add Dyspepsia to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 3 programs from 3 companies, 3 with this as their studies’ main aim; 0 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Dong-A ST and HALEON here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
mosaprideEarlier only
Evidence
  • NCT03225248 · Korea United Pharm. Inc. · Phase 3 · comparator · “Gasmotin” · registered Jul 2017
  • NCT03184402 · Daewoong Pharmaceutical Co. LTD. · Phase 3 · comparator · “Gasmotin” · registered Jun 2017
  • NCT03024086 · Daewoong Pharmaceutical Co. LTD. · Phase 3 · comparator · “Gasmotin” · registered Dec 2016
Lunan Pharmaceutical Group33% of its industry studies00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 3 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Oct 2027 est.lucoridalines · Dong-A ST Co., Ltd. · Phase 4 main aimNCT07686679 A Study to Evaluate the Efficacy and Safety of DA-9701 in Patients With Functional Dyspepsia — primary endpoint: Changes in GIS(Gastrointestinal Symptom Score) total scores · 300 enrolled
  • 10 Nov 2027 est.CnU capsule 500 mg(250mg 2 capsule) · Myungmoon Pharma. Co. Ltd. · Phase 4 main aimNCT07016269 A Study to Evaluate the Efficacy and Safety of CnU Cap. 500 mg in Patients With Biliary Dyspepsia — primary endpoint: Symptom improvement rate at Week 24 using the Global Overall Symptom Scale (GOS) in patients with biliary dyspepsia · 358 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Dyspepsia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Proton pump inhibitors (PPIs) 1 open · Antiemetics 1 open · H2 blockers 1 open · Serotonin receptor agonists 11 · Cholinesterase inhibitors 8

Coming up

20studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 46 Dyspepsia studies recruiting now, 16 (35%) set no upper age limit and 23 (50%) stop at 75 or younger. 2 (4%) take children under 18. 1 (2%) are for women only and 0 (0%) for men only; 8 (17%) take healthy volunteers.

Recruiting studies that take each age, of 46
AgeWomenMen
102 (4%)2 (4%)
1837 (80%)36 (78%)
3043 (93%)42 (91%)
4043 (93%)42 (91%)
5043 (93%)42 (91%)
6538 (83%)37 (80%)
7531 (67%)30 (65%)
8516 (35%)16 (35%)

Across all 372 studies, recruiting or not: 59% stop at 75 or younger and 33% at 65; 9% take children; 3% are for women only and 1% for men only; 24% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Dyspepsia studies take

Of 31 phase 4 interventional studies under Dyspepsia, half reached primary completion within 23 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 313 mo8–33 · 15 studies——
Phase 423 mo11–31 · 31 studies——
Interventional, no phase17 mo9–28 · 79 studies—18 mo9–28 · 71 studies
Observational23 mo12–47 · 22 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 372. Browse all 372 → or search them.